Table 2.
Multivariable Cox regression for the OS among primary NSCLC patients with BM (diagnosed 2010–2014)
| Variables | Number of patients with BM (2010–2014) | Median survival time (95% CI, month) | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Overall (OS) | Deceased (%, OS) | ||||
| Age | 1.159 (1.131–1.188) | < 0.001 | |||
| < 50 | 374 | 326 (87.17%) | 7 (5.961–8.039) | 1.00 | – |
| 50–59 | 1287 | 1181 (91.76%) | 5 (4.531–5.469) | 1.269 (1.122–1.435) | < 0.001 |
| 60–69 | 1998 | 1820 (91.09%) | 5 (4.588–5.412) | 1.344 (1.194–1.514) | < 0.001 |
| 70–79 | 1748 | 1653 (94.57%) | 3 (2.726–3.274) | 1.665 (1.477–1.878) | < 0.001 |
| ≥80 | 745 | 709 (95.17%) | 3 (2.702–3.298) | 1.891 (1.654–2.161) | < 0.001 |
| Race | 0.866 (0.831–0.903) | < 0.001 | |||
| White | 4768 | 4461 (93.56%) | 4 (3.808–4.192) | 1.00 | – |
| Black | 817 | 764 (93.51%) | 3 (2.564–3.436) | 1.047 (0 0.968–1.133) | 0.252 |
| Other | 567 | 464 (81.83%) | 10 (8.451–11.549) | 0.670 (0.608–0.738) | < 0.001 |
| Marital status | |||||
| Unmarried | 2719 | 2554 (93.93%) | 3 (2.768–3.232) | 1.00 | – |
| Married | 3433 | 3135 (91.32%) | 5 (4.705–5.295) | 0.820 (0.777–0.866) | < 0.001 |
| Sex | |||||
| Male | 3600 | 3382 (93.94%) | 4 (3.798–4.202) | 1.00 | – |
| Female | 2552 | 2307 (90.40%) | 5 (4.645–5.355) | 0.805 (0.762–0.850) | < 0.001 |
| Tumor histology | 1.304 (1.245–1.366) | < 0.001 | |||
| Adenocarcinoma | 4268 | 3861 (90.46%) | 5 (4.715–5.285) | 1.00 | – |
| Squamous cell carcinoma | 1560 | 1511 (96.86%) | 3 (2.706–3.294) | 1.354 (1.271–1.442) | < 0.001 |
| Other | 324 | 317 (97.84%) | 2 (1.628–2.372) | 1.558 (1.378–1.761) | < 0.001 |
| Laterality | 1.041 (0.991–1.094) | 0.112 | |||
| Left | 2476 | 2291 (92.53%) | 4 (3.663–4.337) | 1.00 | – |
| Right | 3545 | 3274 (92.36%) | 4 (3.777–4.223) | 1.033 (0.979–1.090) | 0.233 |
| Paired | 131 | 124 (94.66%) | 3 (1.610–4.390) | 1.146 (0.954–1.377) | 0.145 |
| T stage | 1.075 (1.045–1.106) | < 0.001 | |||
| T1 | 506 | 449 (88.74%) | 7 (6.021–7.979) | 1.00 | – |
| T2 | 1674 | 1540 (92.00%) | 5 (4.633–5.367) | 1.190 (1.070–1.323) | 0.001 |
| T3 | 1728 | 1601 (92.65%) | 4 (3.691–4.309) | 1.251 (1.124–1.393) | < 0.001 |
| T4 | 2244 | 2099 (93.54%) | 4 (3.737–4.263) | 1.302 (1.171–1.448) | < 0.001 |
| N stage | 1.050 (1.023–1.078) | < 0.001 | |||
| N0 | 1218 | 1102 (90.48%) | 5 (4.466–5.534) | 1.00 | – |
| N1 | 531 | 479 (90.21%) | 5 (4.273–5.727) | 0.970 (0.871–1.081) | 0.584 |
| N2 | 3118 | 2909 (93.30%) | 4 (3.763–4.237) | 1.139 (1.061–1.222) | < 0.001 |
| N3 | 1285 | 1199 (93.31%) | 4 (3.535–4.465) | 1.114 (1.024–1.212) | 0.012 |
| Grade | 1.143 (1.093–1.194) | < 0.001 | |||
| 1 | 287 | 261 (90.94%) | 6 (4.570–7.430) | 1.00 | – |
| 2 | 1870 | 1686 (90.16%) | 6 (5.484–6.516) | 1.056 (0.927–1.204) | 0.414 |
| 3 | 3845 | 3596 (93.52%) | 4 (3.810–4.190) | 1.247 (1.098–1.416) | 0.001 |
| 4 | 150 | 146 (97.33%) | 3 (2.298–3.702) | 1.350 (1.093–1.668) | 0.005 |
| Brain metastases | |||||
| No | 4722 | 4357 (92.27%) | 4 (3.765–4.235) | 1.00 | – |
| Yes | 1430 | 1332 (93.15%) | 4 (3.713–4.287) | 1.209 (1.134–1.289) | < 0.001 |
| Liver metastases | |||||
| No | 4778 | 4363 (91.31%) | 5 (4.744–5.256) | 1.00 | – |
| Yes | 1374 | 1326 (96.51%) | 3 (2.761–3.239) | 1.378 (1.294–1.468) | < 0.001 |
| Lung metastases | |||||
| No | 4234 | 3904 (92.21%) | 4 (3.767–4.233) | 1.00 | – |
| Yes | 1918 | 1785 (93.07%) | 4 (3.695–4.305) | 1.036 (0.974–1.101) | 0.262 |